Rocket Pharmaceuticals (RCKT) PT Lowered to $7 at Leerink Partners
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Price: $3.51 +0.86%
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Leerink Partners analyst Mani Foroohar lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $7.00 (from $9.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- UBS Downgrades Klarna (KLAR) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
